Furthermore, YG-22 treatment in HCT116 cells demonstrated dose-dependent cytotoxicity, altered gene expression, metabolic reprogramming, chromatin accessibility, and significant modifications in histone and NF-κB binding, highlighting its potential as a therapeutic agent in colorectal cancer. The gene discussed is NFKB1; the disease is colorectal cancer.